eplication-deficient adenovirus (Ad) vectors are attractive strategies for gene therapy or vaccination, and they represent one of the leading platforms in the field of HIV vaccines. However, interest in Ad serotype 5 (Ad5) vectors has waned due to the presence of preexisting Ad5 neutralizing antibodies (NAbs) in a large proportion of the population, particularly in developing countries. The presence of Ad5 NAbs and more recently of Ad-specific cellular immunity has been associated with reduced transduction efficacy and a decrease in the magnitude and breadth of HIVspecific CD4 and CD8 T cells in vaccine recipients (9, 31). Adspecific T cells also recognize epitopes conserved across multiple Ad serotypes (9, 25). Furthermore, a potential correlation between preexisting Ad5 NAb immunity and increased acquisition to HIV infection in vaccine recipients with preexisting Ad5 immunity has been shown in the Step clinical trial (6), which investigated an Ad5 vector vaccine.
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eplication-deficient adenovirus (Ad) vectors are attractive strategies for gene therapy or vaccination, and they represent one of the leading platforms in the field of HIV vaccines. However, interest in Ad serotype 5 (Ad5) vectors has waned due to the presence of preexisting Ad5 neutralizing antibodies (NAbs) in a large proportion of the population, particularly in developing countries. The presence of Ad5 NAbs and more recently of Ad-specific cellular immunity has been associated with reduced transduction efficacy and a decrease in the magnitude and breadth of HIVspecific CD4 and CD8 T cells in vaccine recipients (9, 31) . Adspecific T cells also recognize epitopes conserved across multiple Ad serotypes (9, 25) . Furthermore, a potential correlation between preexisting Ad5 NAb immunity and increased acquisition to HIV infection in vaccine recipients with preexisting Ad5 immunity has been shown in the Step clinical trial (6) , which investigated an Ad5 vector vaccine.
To circumvent the challenges of Ad5 preexisting immunity, several strategies have been developed, including vaccine regimens based on rare adenovirus serotypes (e.g., Ad6, Ad11, Ad26, Ad35, and Ad36) (1, 11, 16, 21) . These rare Ad serotypes may have substantial biological differences, likely resulting from specific interactions with blood components or cell receptors (38) . We and others have shown that Ad vectors derived from various serotypes differentially interact with naïve and memory T cells (2, 27) and human dendritic cells (DCs) (18, 28) and are associated with distinct biological effects in vivo (11, 17) . In this regard, we have recently observed that the formation of immune complexes (ICs) composed of Ad vectors and specific NAbs may have, in addition to reduced transduction efficacy, a differential effect on FcR-expressing cells (29) . Ad5 ICs have been shown to be potent inducers of DC maturation (as assessed by both costimulatory molecule expression and cytokine production) through Fc␥R internalization and Toll-like receptor 9 (TLR9) interaction (29) . Since Ad IC formation likely occurs in subjects with Ad preexisting immunity (7, 22) , we hypothesized (29) that Ad IC-mediated DC maturation may have created more favorable conditions for HIV spread at the port of HIV entry (i.e., mucosal surfaces) and may have contributed to the increased acquisition of HIV infection in vaccinees with preexisting Ad5 immunity in the Step trial.
In the present study, we have evaluated the potency of ICs formed by common and rare Ad-derived vectors (i.e., Ad5, Ad6, Ad26, Ad35, Ad36, and Ad41 vectors) and human plasma to mature human DCs derived from monocytes, as previously described (28) . We showed that ICs generated with rare Ad vector serotypes such as Ad26 and Ad35, which are lead candidates in HIV vaccine development, are poor inducers of DCs maturation and that their potency in inducing DC maturation strongly correlated with the number of TLR9-agonist motifs present in the Ad vector's genome. In addition, we showed that antihexon but not antifiber antibodies are responsible for induction of Ad IC-mediated DC maturation.
MATERIALS AND METHODS
Blood mononuclear cell and DC isolation. Blood samples were obtained from 10 volunteers at the local blood bank (Lausanne, Switzerland). Isolation of blood mononuclear cells and generation of monocyte-derived DCs (MoDCs) were performed as previously described (28) .
Adenovirus vectors. Two E1-and E3-deleted Ad5 vectors (Ad5␤gal and Ad5GFP) were used in this study and were previously described (26) . Briefly, Ad␤gal harbors a lacZ expression cassette and was used to assess Ad-mediated DC maturation. Ad5GFP harbors a green fluorescent protein (GFP) expression cassette and was used for the assessment of NAb titers. E1-deleted Ad6-secreted alkaline phosphatase (SEAP), E1-E4-and orf6-deleted Ad26-SEAP, and E1-, E4-, and orf6-deleted Ad36-SEAP vectors were provided by Merck and have already been described (19) . E1-and E3-deleted Ad35-luc (16) and E1-and E3-deleted Ad5-luc harboring hypervariable regions 1 to 7 of Ad48 (Ad5HVR1-7) (32) were provided by Dan Barouch. E1-deleted Ad41-GFP (17) and E1-deleted Ad5-luc harboring Ad35 fiber (Ad5F35) (24) were provided by Genvec and have already been described. Ad vector titers were measured in virus physical particles (pp) per cell, as described by Mittereder et al. (23) . Ad genome sequences are available in http://www.ncbi.nlm.nih.gov/nuccore under the following accession numbers: Ad5, AY339865.1; Ad6, HQ413315.1; Ad26, EF153474.1; Ad35, AC_000019.1; Ad36, GQ384080.1; and Ad41, DQ315364.
NAb titers. Ad5 and Ad41 NAb titers of 19 plasma samples were determined by transduction inhibition assays on human embryonic retina (HER; 911 cells [8] ) as previously described (26) . The NAb titers were expressed as the inverse of the highest dilution of each plasma sample that gave at least 50% reduction of transduction. Ad6, Ad26, and Ad36 NAb titers were provided by Merck and are expressed as the inverse of the highest dilution of each plasma sample that gave at least 50% reduction of secreted alkaline phosphatase (SEAP), as previously described (19) . Ad35 NAb titers were provided by Dan Barouch and determined as previously described (3) .
Expression of costimulatory molecules and cytokine secretion. DCs (3 ϫ 10 5 in 500 l of complete medium) were exposed to the Ad5␤gal, Ad6, Ad26, Ad35, Ad36, or Ad41 vectors alone (2 ϫ 10 4 pp/cell), or Ad ICs for 36 h. Ad ICs were composed of Ad vector (2 ϫ 10 4 pp/cell) mixed with 15 l of plasma for 15 min at room temperature. As negative and positive controls, DCs were either cultured with medium alone or stimulated with TLR7/8 agonist R848 (1 g/ml; Invivogen). At the end of the incubation period, cells were stained with anti-CD86 -allophycocyanin (APC) (clone 2331 [FUN-1]) (BD Biosciences), and expression of the CD86 costimulatory molecule was assessed by flow cytometry on an LSRII four-laser cytometer (405, 488, 532, and 633 nm) and analyzed using FlowJo (version 8.8.6). Supernatants were collected and analyzed for the presence of tumor necrosis factor alpha (TNF-␣) by Luminex (Panomics, Italy).
TLR9 inhibition.
DCs were pretreated (2 h at 37°C) with phosphorothioate-protected IRS 869 (TLR9 inhibitor; 5 M; Sigma) or control oligonucleotide (ODN; Sigma) and then exposed to Ad5, Ad6, Ad26, or Ad36 vector alone, plasma containing serotype-specific NAbs (n ϭ 3 per Ad tested) alone, or Ad ICs for 18 h, as previously described (29) . Supernatants were collected and analyzed for the presence of TNF-␣ by Luminex (Panomics, Italy).
Statistical analyses. P values were derived from one-way analysis of variance (ANOVA) (Kruskal-Wallis test) followed by Student's t test or using Spearman's rank test for correlations. Statistical calculations were performed in GraphPad Prism version 5.04 as previously described (30) .
RESULTS

Differential effects of common versus rare adenovirus vectors forming ICs on DC maturation.
The effects of Ad ICs on DC maturation were assessed by investigating measures of DC maturation such as upregulation of costimulatory molecule expression (i.e., CD86) and production of proinflammatory cytokines (i.e., TNF-␣). To exclude the possibility that the effects were due to complement activity, heat-inactivated sera (30 min at 56°C) were used throughout this study.
Consistent with previous studies (29), we found that Ad5 vector alone, plasma alone, or Ad5 ICs formed with plasma containing low Ad5-NAb titers (NAb titers Ͻ 18), determined as previously described (26) , modestly increased CD86 expression on DCs ( Fig. 1A and B) . Similarly, no significant increase in CD86 expression was observed in DCs exposed to Ad6, Ad26, Ad35, Ad36 or Ad41 vectors alone (Fig. 1B) . However, significant increases (P Ͻ 0.05) in CD86 expression were observed in the presence of Ad ICs formed with Ad-serotype-specific NAbs (NAb titers Ͼ 200) but (Fig. 1B) . Interestingly, Ad26, Ad35, and Ad36 ICs formed with serotype-specific NAbs, determined as previously described (3, 19) , induced significantly lower CD86 expression (P Ͻ 0.005) than Ad5 ICs (Fig. 1B) .
Unstimulated DCs and DCs exposed to Ad5 vector alone or plasma alone did not produce TNF-␣ ( Fig. 2A) (29) . However, DCs exposed to Ad ICs formed with Ads and plasma containing Ad-serotype-specific NAbs (NAb titers Ͼ 200) significantly induced the production of TNF-␣ compared to DCs exposed to Ad ICs formed with plasma containing low NAb titers (NAb titers (Fig. 2B) . Interestingly, Ad26, Ad35, and Ad36 induced lower levels of TNF-␣ production than Ad5 and Ad6, while Ad41 induced intermediate levels of TNF-␣ production (Fig. 2B) . Furthermore, the levels of TNF-␣ production directly correlated with the titers of serotype-specific NAbs for Ad5 (P Ͻ 0.0001), Ad6 (P Ͻ 0.0002), Ad36 (P Ͻ 0.0005), and Ad41 (P Ͻ 0.0001) but not for Ad26 and Ad35, and the induction of TNF-␣ production was strictly dependent on the specificity of the NAbs (Fig. 2B, Fig. 3 , and Tables 1, 2 , and 3). Of note, as previously shown for Ad5 ICs (29) , Ad ICs induced production of other cytokines, such as type I interferons (IFNs). The levels of IFN-␣ and IFN-␤ directly correlated with the titers of serotype-specific NAbs for Ad5 (P ϭ 0.009 and P ϭ 0.006), Ad6 (P ϭ 0.03 and P ϭ 0.003), Ad36 (P Ͻ 0.05 and P Ͻ 0.05), and Ad41 (P Ͻ 0.05 and P Ͻ 0.05) but not for Ad26 and Ad35 ( Fig. 2C and D) .
The number of TLR9-agonist motifs (GTCGTT) in adenoviral genome sequences directly correlates with the level of DC maturation. We have recently shown that Ad5 ICs formed with ⌬E1 Ad5 vector (vector deleted in the E1 regions), but not with the helper-dependent Ad5 vector (HD-Ad5) (vector deleted in all viral genes), triggered DC maturation, underscoring the role of Ad5 DNA genome in Ad5 IC-mediated DC maturation (29) . We therefore first assessed the role of Ad DNA-TLR9 interaction in Ad IC-mediated DC maturation (assessed by TNF-␣ production) with Ad ICs formed with common versus rare Ad serotypes (i.e., Ad5, Ad6, Ad26, and Ad36). The results obtained clearly indicate that TLR9 antagonist (IRS 869) significantly reduced TNF-␣ production by Ad5 IC-, Ad6 IC-, Ad26 IC-, and Ad36 IC-mediated DC maturation (Fig. 4) , supporting the role of TLR9 in Ad ICmediated DC maturation. This observation is consistent with previous studies that showed that Ad DNA interaction with TLR9 triggers DC maturation (15, 29) .
We then investigated whether specific regions of the Ad5 genome were involved in DC maturation. Thus, we determined the presence of GTCGTT motifs that were shown to stimulate human TLR9-expressing cells (4, 14) within each Ad vector sequence genome. We found that the number of GTCGTT motifs varied among different Ad vector serotypes (Fig. 5A) . Interestingly, the number of GTCGTT motifs present in each Ad vector genome sequence correlated with the potency of Ad IC-mediated DC maturation (i.e., CD86 expression and TNF-␣ production; P ϭ 0.0028 and P ϭ 0.0054, respectively) ( Fig. 5B and C) . CD46 signaling does not interfere with Ad IC-mediated DC maturation. The cellular attachment protein for Ad belonging to the subgroups A, C (including Ad5 and Ad6), D (including Ad36), and E and F (including Ad41) is mediated by coxsackievirus-adenovirus receptor (CAR) interactions, while CD46 is used for some Ads belonging to subgroup B (including Ad35), and D (including Ad26) (1, 5, 10, 33-36, 40). Since both Ad26 ICs and Ad35 ICs triggered a reduced DC maturation compared to Ad5 ICs, we therefore investigated the potential role of Ad-CD46 interaction on Ad IC-mediated DC maturation. To address this issue, DCs were exposed to Ad35 (which binds only to CD46) either prior to, at the time of, or post-Ad5 IC stimulations. The results indicate that CD46 signaling did not interfere with Ad5 IC-mediated DC maturation (assessed by TNF-␣ production) (Fig. 6) .
Antihexon but not antifiber antibodies are responsible for inducing Ad IC-mediated DC maturation. Ad5 neutralization may be mediated by either antifiber antibodies through the aggregation of the virions (extracellular neutralization) or by antihexon antibodies through the blocking of the endosomal escape or dissociation (intracellular neutralization) (39). Next we investigated which type of NAbs (i.e., antifiber or antihexon) induced DC maturation. DCs were exposed to ICs formed by plasma containing Ad5 NAbs (NAb titer of 512), and Ad5, or Ad5F35 vector (chimeric Ad5 vector engineered with Ad35 fiber) or Ad5HVR1-7 vector (chimeric Ad5 vector engineered with the hypervariable regions [HVR] 1 to 7 of Ad48) (24, 32) . Therefore, the role of Ad5 antihexon selective neutralizing activity in Ad5 IC-mediated DC maturation can be assessed following the formation of Ad5HVR1-7 ICs, while the role of antifiber neutralizing activity in Ad5 ICmediated DC maturation can by assessed by the formation of Ad5F35 ICs. Of note, the plasma samples tested were Ad35 and Ad48 seronegative (NAb titer Ͻ 16). The results obtained showed that about 90% of Ad5 IC-mediated DC maturation activity as assessed by TNF-␣ production was observed with Ad5F35 ICs, thus indicating that antihexon antibodies directed to hypervariable regions 1 to 7 of the hexon protein were almost exclusively responsible for DC maturation (Fig. 7) . 
DISCUSSION
In 2007, the phase IIb test-of-concept efficacy study called
Step, which evaluated a trivalent Ad5-Gag/Pol/Nef vaccine candidate, was prematurely terminated due to the lack of efficacy of the vaccine (6, 20) . Unexpectedly, uncircumcised vaccine recipients with higher titers of Ad5 NAbs (Ad5 titers Ͼ 18) showed increased susceptibility to HIV infection compared to vaccine recipients with lower titers (Ͻ18) of Ad5 NAbs and/or circumcised and placebo recipients (6) . Several hypotheses were proposed to explain the increased acquisition of HIV infection among vaccine recipients of the Step trial. In this regard, we showed that DCs exposed to Ad5 ICs but not Ad5 vector alone induced a strong maturation of DCs that enhanced HIV infection of DC-CD4 T cell coculture (29) . We also demonstrated that Ad5 IC-mediated DC maturation required Ad5 IC internalization through Fc␥RII receptor followed by TLR9 engagement (29) . We hypothesized that Ad IC-mediated DC maturation may create more favorable conditions for HIV spreading in CD4 T cells at the mucosal level in vaccinees with preexisting Ad5 immunity in the Step trial. Of note, the central role of DCs in transmitting HIV to antigen-specific CD4 T cells was later supported by Gringhuis et al. (13) . Furthermore, the results from the a Thirteen plasma samples harboring distinct Ad-serotype specific NAbs (Table 2) were mixed with Ad5, Ad6, Ad26, or Ad36 to form ICs and exposed to DCs. Following 36 h of incubation, supernatants were collected and TNF-␣ production (pg/ml) was monitored by Luminex.
FIG 4 Ad IC-mediated DC maturation requires TLR9 interaction. MoDCs
were stimulated with Ad5, Ad6, Ad26, or Ad36 IC (with three distinct sera containing NAbs) in the presence or absence of TLR9 inhibitor (IRS 869). At the end of the stimulation period, supernatants were analyzed for the presence of TNF-␣. Results are expressed as the percentages of the cytokine levels measured in cultures treated with TLR9 inhibitor versus those found in control cultures (absence of inhibitors). The experiment described above was performed in triplicate. Statistical significance (P values) was obtained using Student's t test.
FIG 5
The number of TLR9 agonist motifs (GTCGTT) in adenoviral genome sequences directly correlates with the level of DC maturation. Schematic representation of GTCGTT motif positions in Ad5, Ad6, Ad26, Ad35, Ad36, and Ad41 genome sequences (A). The number of TLR9 agonist sequences (GTC GTT) in Ad5, Ad6, Ad26, Ad35, Ad36, and Ad41 genome sequences directly correlates with the level of DC maturation as assessed by CD86 expression (B) and TNF-␣ production (C). Statistical significance (P values) in panels B and C was obtained using Spearman's rank correlations.
Step trial have further underscored the potential emergence of safety issues in subjects with preexisting immunity against viral vector-based vaccines. It is therefore of paramount importance to determine the immunological effects that may be triggered in subjects with preexisting immunity when they reencounter adenovirus following vaccination with Ad vector-based vaccines.
In the present study, we extended our previous observations with Ad5 to investigate the potential impact of preexisting humoral immunity to Ad vectors based on rare Ad serotypes such as Ad6, Ad26, Ad35, Ad36, and Ad41. For these purposes, we have used an in vitro experimental system that allows us to determine the effect of Ad antibody preexisting immunity on DC maturation. Rare Ad serotype vectors such as Ad26 and Ad35 are being used to develop vaccines in the fields of HIV, tuberculosis, and malaria research.
Of interest, we have demonstrated major biological differences in rare Ad serotypes such as Ad26, Ad35, and Ad36 ICs and Ad5 and Ad6 ICs in terms of the ability to stimulate maturation of DCs. Ad26, Ad35, and Ad36 ICs were poor inducers of DC maturation compared to Ad5 and Ad6 ICs. We previously shown that Ad DNA-TLR9 interaction was responsible for DC maturation mediated by Ad5 ICs. In the present study, we provide evidence that the same TLR9 mechanism is operating in the DC maturation mediated by rare Ad IC serotypes.
Almost a decade ago, two independent studies showed that a particular hexamer motif (GTCGTT) had a strong capacity to stimulate human TLR9-expressing cells (4, 14) . We therefore investigated whether there was a relationship between the number of hexamer motifs (GTCGTT) within common and rare Ad-derived vector genomes (i.e., Ad5, Ad6, Ad26, Ad35, Ad36, and Ad41 vectors) and their ability to induce DC maturation. We found that the number of GTCGTT motifs, which varied among different Ad genome sequences, correlated with the potency of Ad ICs to induce DC maturation. Of note, these motifs are located outside the E1, E3, and E4 genes, which are the genes being deleted in the different Ad5 vector HIV vaccine candidates evaluated in different clinical trials.
Ad5, Ad6, Ad36, and Ad41 utilized CAR as a cellular receptor, while Ad26 and Ad35 utilize CD46 (1, 5, 10, (33) (34) (35) (36) 40) . It is therefore possible that the biological differences observed between common and rare Ad serotypes in stimulating DC maturation resulted from a different receptor usage rather than from the number of GTCGTT motifs and TLR9 interaction. However, three observations in the present study support the importance of the number of TLR9-agonist motifs as primary mechanism to explain the potency of the different Ad ICs in the maturation of DCs. First, Ad36 utilizes CAR, and it is a poor inducer of DC maturation, like Ad35 and Ad26, which utilize CD46. Therefore, the difference between Ad36 and Ad5 or Ad6 relies on the number of TLR9-agonist motifs and not on receptor usage. Second, treatment of DCs with Ad35, which potentially delivers via CD46 an inhibitory signal to DCs, did not prevent DC maturation mediated by Ad5 ICs that utilize CAR. Third, Ad5F35 ICs (Ad5 pseudotyped with Ad35 fiber), which can interact with CD46 and harbor an equal number of TLR9 agonist motifs to Ad5 (n ϭ 7), had similar potency in mediating DC maturation (assessed by TNF-␣ production) compared to Ad5 ICs. Therefore, CD46 signaling did not interfere with Ad IC-mediated DC maturation via CAR.
Finally, we showed that antihexon but not antifiber antibodies are responsible for inducing DC maturation. Since antihexon NAbs may prevent capsid disassembly and nuclear entry of viral DNA by cross-linking the viral particles (37), it is likely that Ad5 ICs may stabilize the capsid at endosomal pH (pH 6), which might prevent at least in part the endosomal escape of Ad5 DNA (12) .
In conclusion, the present study provides new insights into the biological differences between Ad serotypes and their potential interaction with the host immune system in the presence of preexisting immunity. However, the potential role of Ad IC-mediated DC maturation in creating favorable conditions for HIV spread in vivo remains to be determined. Notwithstanding the limited knowledge of the tropism of the rare Ad serotypes in vivo, one may speculate that the lack of induction of DC maturation by Ad26 and Ad35 ICs together with the low seroprevalence may render rare Ad serotype vectors an attractive platform for the vaccine field.
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FIG 7
Ad5 IC-mediated TNF-␣ production is due to anti-hypervariable region 1 to 7 NAbs but not to antifiber antibodies. MoDCs were stimulated with 3 distinct sera alone containing NAbs (Ad5 NAbs; n ϭ 512), Ad5, Ad35, Ad48, Ad5F35, or Ad5HVR1-7 vectors alone or Ad ICs formed with the plasma and vectors described above. Following 36 h of incubation, supernatants were collected and analyzed for the presence of TNF-␣. Results are expressed as the percentage of the cytokine levels measured in cell culture exposed to Ad5 ICs versus those found in Ad35, Ad48, Ad5F35, or Ad5HVR1-7 ICs. The experiment described above was performed in triplicate.
FIG 6
CD46 signaling does not interfere with Ad IC-mediated DC maturation. MoDCs were stimulated with Ad5 IC formed with 3 distinct sera containing NAbs (Ad5 NAbs, n ϭ 512) in the presence or absence of Ad35 (preAd5 IC stimulation, poststimulation, or at the time of stimulation). Following 36 h of incubation, supernatants were collected and analyzed for the presence of TNF-␣. Results are expressed as the percentage of the cytokine levels measured in cell culture exposed to Ad35 versus those found in Ad5 IC alone. The experiment described above was performed in triplicate. Statistical significance (P values) was obtained using Student's t test.
